Commerzbank Sells 39,586 AbbVie Shares, Cuts Stake by 30.5%
In the third quarter, Commerzbank Aktiengesellschaft FI trimmed its AbbVie holdings by 30.5%, selling 39,586 shares and retaining 90,102 shares valued at $20.86 million, according to its latest 13F filing. Meanwhile, Norges Bank initiated a new AbbVie position worth approximately $4.29 billion during the period.
1. Dividend Kings Performance and AbbVie Exposure
In 2025, Dividend Kings collectively returned an average of 4.91% versus the S&P 500’s 17.72% total return, though 14 kings outperformed the index. Through January 23, 2026, the Dividend Kings group rose 4.66%, outpacing the index’s 1.07% gain. Notably, AbbVie has been highlighted as one of the 19 Dividend Kings that appear undervalued and offer at least 10% long-term annualized expected returns, underscoring its attractive yield profile and stability of cash flows within a challenging market environment.
2. Institutional Trading Activity in AbbVie Shares
During the third quarter, Commerzbank Aktiengesellschaft FI reduced its stake in AbbVie by 30.5%, selling 39,586 shares and ending the period with 90,102 shares valued at approximately 20.9 million. Meanwhile, major institutional investors such as Norges Bank initiated a new position worth about 4.29 billion, and Vanguard Group increased its holding by 1.9% to 177.3 million shares. DZ BANK AG raised its position by 169.3% to 4.7 million shares, and Raymond James Financial added 2.8 million shares (up 41.8%), bringing its total to 9.3 million. Institutional ownership now stands at 70.23%.
3. Analyst Ratings and Consensus Targets
AbbVie’s consensus rating remains a “Moderate Buy,” supported by two Strong Buy recommendations, thirteen Buys and eight Holds. Recent research reports include Morgan Stanley’s upgrade to Overweight with a target of 269 and Berenberg Bank’s objective of 275. UBS reiterated a Neutral view in mid-January, while Citigroup and Erste Group Bank both maintain neutral/hold stances. BMO Capital Markets continues to endorse an Outperform rating. The implied consensus price target across 23 analysts is approximately 248.11.
4. Q3 Earnings, Guidance and Dividend Increase
In the third quarter, AbbVie delivered revenue growth of 9.1% year-over-year, generating 15.78 billion in sales and reporting EPS of 1.86, which topped consensus by 0.09. The company’s net margin stood at 4.00%, and return on equity exceeded 3,200%. AbbVie guided Q4 EPS to a range of 3.320–3.360. In January, the board approved a 5.5% quarterly dividend increase to 1.73 per share, translating to an annualized payout of 6.92 and a yield of approximately 3.2%, with a payout ratio of 524.2%.